Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 3/20 | 0.42 |
| ▸ | RAB9A | P51151 | 3/20 | 0.42 |
| ▸ | CASP3 | P42574 | 1/20 | 0.42 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.42 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.42 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.42 |
| ▸ | HPGDS | O60760 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 2/20 | 0.41 |
| ▸ | MITF | O75030 | 1/20 | 0.40 |
| ▸ | BRD2 | P25440 | 1/20 | 0.40 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.40 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.39 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12377821 | 0.84 | MAPT (0.46) | KMT2ATSHRNPC1RAB9ACASP3 | |
| SCHEMBL24483836 | 0.81 | MAPT (0.42) | KMT2ANPC1RAB9AALDH1A1MEN1 | |
| SCHEMBL5778990 | 0.81 | ACHE (0.43) | KMT2AADORA2BNPC1RAB9AALDH1A1 | |
| SCHEMBL14667331 | 0.81 | HRH4 (0.43) | KMT2ATSHRNPC1RAB9ACASP3 | |
| SCHEMBL2284851 | 0.80 | MAPT (0.36) | KMT2ANPC1RAB9ACASP3SENP8 | |
| SCHEMBL27930459 | 0.78 | ALDH1A1 (0.43) | KMT2ATSHRALDH1A1MEN1 | |
| SCHEMBL24469892 | 0.78 | CA2 (0.38) | KMT2ATSHRALDH1A1MEN1 | |
| SCHEMBL12041227 | 0.77 | KMT2A (0.46) | KMT2ATSHRBRD4BRD2PTGS1 | |
| SCHEMBL9771829 | 0.77 | NPC1 (0.44) | KMT2ATSHRNPC1RAB9ACASP3 | |
| SCHEMBL5778006 | 0.76 | ALDH1A1 (0.50) | KMT2AADORA2BNPC1RAB9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016077541-A1 | NOVEL ANTI-INFECTIVE COMPOUNDS AND METHODS USING SAME | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2016-05-19 | — | — | WO | claimed |
| WO-2016077541-A1 | NOVEL ANTI-INFECTIVE COMPOUNDS AND METHODS USING SAME | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2016-05-19 | — | — | WO | disclosed |
| US-8889674-B2 | Piperidine and pyrrolidine derivatives having NPY Y5 receptor antagonism | SHIONOGI & CO., LTD. (JP) | 2014-11-18 | — | — | US | disclosed |
| EP-2404902-A1 | PIPERIDINE AND PYRROLIDINE DERIVATIVES HAVING NPY Y5 RECEPTOR ANTAGONISM | Shionogi&Co., Ltd. (JP) | 2012-01-11 | — | — | EP | disclosed |
| US-20110319412-A1 | PIPERIDINE AND PYRROLIDINE DERIVATIVES HAVING NPY Y5 RECEPTOR ANTAGONISM | SHIONOGI & CO., LTD. (JP) | 2011-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319412-A1 | PIPERIDINE AND PYRROLIDINE DERIVATIVES HAVING NPY Y5 RECEPTOR ANTAGONISM | NPY5R, NPY1R, NPY2R | KMT2A 2734/4885TSHR 126/4885ADORA2B 895/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.